Paper Details

  1. Home
  2. Paper Details

Safety and Tolerability of Intravenous Valproic Acid in Healthy Subjects: A Phase I Dose-Escalation Trial.

Author: AlamHasan B, BonhamTess, GeorgoffPatrick E, HalaweishIhab, LuoRuijuan, NikolianVahagn C, PaiManjunath P, ParameswaranAishwarya, SunDuxin, TafatiaCelia, ToKathleen, WatcharotoneKuanwong

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Overview

This trial determined the maximum tolerated single dose of intravenous valproic acid in healthy humans.
Paper Details　
Original Abstract of the Article :
Valproic acid, a histone deacetylase inhibitor, has beneficial effects in the setting of cancer, neurologic diseases, and traumatic injuries. In animal models of traumatic injury, a single dose of valproic acid has been shown to reduce mortality. The purpose of this trial was to determine the maximu...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/28497259

データ提供：米国国立医学図書館（NLM）

Valproic Acid: A Promising New Drug with Potential Applications in Various Fields

The world of [medicine] is constantly evolving, with exciting new drugs being developed to treat various conditions. This study focuses on [valproic acid], a [histone deacetylase inhibitor] that has shown promise in treating [cancer], [neurological diseases], and [traumatic injuries].

The study aimed to determine the [maximum tolerated dose] of [intravenous valproic acid] in healthy individuals. Researchers carefully administered increasing doses of the drug to participants, monitoring for any [adverse effects].

The results of this phase I trial demonstrated that [intravenous valproic acid] is [well-tolerated] within a specific dose range. These findings provide valuable information for future research on the potential therapeutic applications of [valproic acid] in various medical fields.

A New Frontier in Drug Development: Valproic Acid's Potential

This research suggests that [valproic acid] might become a valuable tool in the treatment of various diseases. Its potential benefits in [cancer], [neurological diseases], and [traumatic injuries] warrant further investigation to explore its therapeutic efficacy and safety.

The Future of Valproic Acid: Exciting Possibilities

The development of [valproic acid] as a potential treatment option is a testament to the ongoing progress in medical research. As we continue to learn more about its effects and applications, it may become an essential tool in the arsenal of medications for a wide range of conditions.

Dr.Camel's Conclusion

This study marks an exciting development in the world of [medicine]. The potential of [valproic acid] to treat various conditions is a testament to the power of scientific innovation. While further research is needed to fully explore its applications, this study offers a glimpse into a future where [valproic acid] might become a valuable therapeutic agent for patients around the world.

Date :
  1. Date Completed 2019-05-16
  2. Date Revised 2020-08-27
Further Info :

Pubmed ID

28497259

DOI: Digital Object Identifier

NIHMS917868

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.